PE20212197A1 - Formas de sal y cristalinas de un compuesto organico y composiciones farmaceuticas del mismo - Google Patents

Formas de sal y cristalinas de un compuesto organico y composiciones farmaceuticas del mismo

Info

Publication number
PE20212197A1
PE20212197A1 PE2021001052A PE2021001052A PE20212197A1 PE 20212197 A1 PE20212197 A1 PE 20212197A1 PE 2021001052 A PE2021001052 A PE 2021001052A PE 2021001052 A PE2021001052 A PE 2021001052A PE 20212197 A1 PE20212197 A1 PE 20212197A1
Authority
PE
Peru
Prior art keywords
salt
methyl
pharmaceutical compositions
organic compound
crystalline forms
Prior art date
Application number
PE2021001052A
Other languages
English (en)
Inventor
Syed Altaf
Abira Ramakrishnan
Jacob Sizemore
Shijie Zhang
Original Assignee
Les Laboratoires Servier Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier Sas filed Critical Les Laboratoires Servier Sas
Publication of PE20212197A1 publication Critical patent/PE20212197A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA SAL DE TRIS(HIDROXIMETIL)AMINOMETANO DE UN COMPUESTO REPRESENTADO POR LA FORMULA DEL COMPUESTO 1 (ACIDO 1-METIL-5-(2'-METIL-[1,1'-BIFENIL]-IL)-1H-BENZO[D][1,2,3]TRIAZOL-7-CARBOXILICO), EN DONDE LA SAL ES LA FORMA A CRISTALINA CARACTERIZADA POR PICOS DE DIFRACCION DE RAYOS X EN POLVO EN ANGULOS 2? (± 0,2°) DE 4,4°, 15,6° Y 18,9°. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHO COMPUESTO ACIDO 1-METIL-5-(2'-METIL-[1,1'-BIFENIL]-IL)-1H-BENZO[D][1,2,3]TRIAZOL-7-CARBOXILICO ES UN INHIBIDOR DE LA DIHIDROOROTATO DESHIDROGENASA (DHODH) SIENDO UTIL EN EL TRATAMIENTO DE CANCER Y ENFERMEDADES AUTOINMUNITARIAS.
PE2021001052A 2018-12-21 2019-12-20 Formas de sal y cristalinas de un compuesto organico y composiciones farmaceuticas del mismo PE20212197A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862784083P 2018-12-21 2018-12-21
US201962791571P 2019-01-11 2019-01-11
US201962882712P 2019-08-05 2019-08-05
PCT/US2019/067897 WO2020132471A1 (en) 2018-12-21 2019-12-20 Crystalline and salt forms of an organic compound and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
PE20212197A1 true PE20212197A1 (es) 2021-11-16

Family

ID=69185721

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021001052A PE20212197A1 (es) 2018-12-21 2019-12-20 Formas de sal y cristalinas de un compuesto organico y composiciones farmaceuticas del mismo

Country Status (20)

Country Link
US (1) US20220055995A1 (es)
EP (1) EP3898597A1 (es)
JP (1) JP2022515239A (es)
KR (1) KR20220035022A (es)
CN (1) CN113508108A (es)
AU (1) AU2019403396A1 (es)
BR (1) BR112021012305A2 (es)
CA (1) CA3124401A1 (es)
CL (1) CL2021001640A1 (es)
CO (1) CO2021009309A2 (es)
CR (1) CR20210394A (es)
IL (1) IL284218A (es)
JO (1) JOP20210147A1 (es)
MA (1) MA54541A (es)
MX (1) MX2021007536A (es)
NI (1) NI202100055A (es)
PE (1) PE20212197A1 (es)
SG (1) SG11202106526UA (es)
TW (1) TW202039448A (es)
WO (1) WO2020132471A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111757731A (zh) 2018-02-20 2020-10-09 安吉奥斯医药品有限公司 三取代苯并三唑衍生物的使用方法
CA3190511A1 (en) 2020-08-27 2022-03-03 John COCO Use of a dhodh inhibitor compound in combination cancer therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2228367A1 (en) * 2009-03-13 2010-09-15 Almirall, S.A. Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
TWI598336B (zh) 2011-04-13 2017-09-11 雅酶股份有限公司 經取代之苯化合物
US9360932B1 (en) 2012-08-29 2016-06-07 Intellect Motion Llc. Systems and methods for virtually displaying real movements of objects in a 3D-space by means of 2D-video capture
CN103965133B (zh) * 2013-01-31 2018-11-30 华东理工大学 一种具有dhodh抑制活性的含n、s杂环化合物及其制备和用途
HUE042032T2 (hu) 2013-02-25 2019-06-28 Aurigene Discovery Tech Ltd Triszubsztituált benzotriazol-származékok, melyek dihidro-orotát-oxigenáz-inhibitor hatásúak
US20180369206A1 (en) * 2017-04-24 2018-12-27 Aurigene Discovery Technologies Limited Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors

Also Published As

Publication number Publication date
WO2020132471A1 (en) 2020-06-25
EP3898597A1 (en) 2021-10-27
MX2021007536A (es) 2021-09-23
AU2019403396A1 (en) 2021-07-08
SG11202106526UA (en) 2021-07-29
CA3124401A1 (en) 2020-06-25
BR112021012305A2 (pt) 2021-10-05
CN113508108A (zh) 2021-10-15
NI202100055A (es) 2021-12-01
US20220055995A1 (en) 2022-02-24
MA54541A (fr) 2022-03-09
IL284218A (en) 2021-08-31
JOP20210147A1 (ar) 2023-01-30
CR20210394A (es) 2021-12-13
TW202039448A (zh) 2020-11-01
WO2020132471A8 (en) 2020-08-06
CO2021009309A2 (es) 2021-10-29
KR20220035022A (ko) 2022-03-21
JP2022515239A (ja) 2022-02-17
CL2021001640A1 (es) 2022-06-03

Similar Documents

Publication Publication Date Title
PH12016501204A1 (en) Syk inhibitors
EA201790088A1 (ru) Ингибиторы syk
MX2020010300A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
EA201690094A1 (ru) Ингибиторы syk
EA201700230A1 (ru) Определенные аминопиридины, композиции на их основе и способы их применения
PE20181888A1 (es) Formulaciones liquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
JP2016510769A5 (es)
PH12015502802A1 (en) Formulation comprising a hypolipidemic agent
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
PE20212197A1 (es) Formas de sal y cristalinas de un compuesto organico y composiciones farmaceuticas del mismo
WO2008109991A8 (en) Inhibitors of carnitine palmitoyltransferase and treating cancer
MX2017005422A (es) Inhibidores de histona desacetilasa y sus usos en terapia.
BR112015004523A2 (pt) compostos de tetraciclina
NZ707366A (en) Novel histone deacetylase inhibitors and their use in therapy
CL2020001420A1 (es) Procedimiento para la preparación de (3s)-3-(4-cloro-3-{[(2s,3r)-2-(4-clorofenil)-4,4,4-trifluor-3-metilbutanoil] amino}fenil)-3-ácido ciclopropilpropanoico y su forma cristalina para uso como principio activo farmacéutico.
TR201908676T4 (tr) Mesane idrar yolu hastalıklarının önlenmesinde veya tedavisinde kullanıma yönelik 2-asilaminotiyazol türevi.
WO2010132670A3 (en) Pentacycline compounds
CO2022006929A2 (es) Forma cristalina de un derivado del ácido 7h-benzo[7]anuleno-2-carboxílico
PE20210415A1 (es) Forma de dosificacion farmaceutica administrable por via oral con liberacion modificada
NZ623265A (en) Stilbenoid compounds as inhibitors for squamous carcinoma and hepatoma and uses thereof
MX2015010434A (es) Derivados de acido bisfenil-butanoico sustituido como inhibidores de la endopeptidasa neutra (nep), con una mayor eficacia in vivo.
AU2017299850A8 (en) Solid forms of TTK inhibitor
TW202417446A (zh) 含氮雜環化合物、其藥物組合物及應用
TH135149B (th) สารรักษาโรคหรือป้องกันโรคสำหรับโรคทางเดินน้ำดี